IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ANDREOLI, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.325
EU - Europa 7.923
AS - Asia 7.770
SA - Sud America 1.750
Continente sconosciuto - Info sul continente non disponibili 473
AF - Africa 238
OC - Oceania 22
AN - Antartide 1
Totale 32.502
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.024
SG - Singapore 2.658
CN - Cina 2.261
DE - Germania 2.253
BR - Brasile 1.452
UA - Ucraina 1.201
IT - Italia 1.039
HK - Hong Kong 1.007
PL - Polonia 778
RU - Federazione Russa 633
VN - Vietnam 621
FI - Finlandia 457
FR - Francia 455
GB - Regno Unito 406
TR - Turchia 304
BD - Bangladesh 281
IE - Irlanda 240
IN - India 178
CA - Canada 142
AR - Argentina 110
SE - Svezia 89
MX - Messico 82
NL - Olanda 73
ZA - Sudafrica 73
IQ - Iraq 65
EC - Ecuador 53
JP - Giappone 52
ID - Indonesia 49
ES - Italia 46
NG - Nigeria 39
AT - Austria 38
PK - Pakistan 38
CO - Colombia 36
SA - Arabia Saudita 33
CZ - Repubblica Ceca 31
VE - Venezuela 30
UZ - Uzbekistan 27
MA - Marocco 26
EG - Egitto 23
AU - Australia 21
BE - Belgio 21
JO - Giordania 21
PY - Paraguay 21
AE - Emirati Arabi Uniti 18
CL - Cile 18
PH - Filippine 17
CH - Svizzera 16
DZ - Algeria 16
JM - Giamaica 16
CR - Costa Rica 15
EU - Europa 15
GR - Grecia 15
KE - Kenya 15
PE - Perù 14
TH - Thailandia 14
HR - Croazia 13
KZ - Kazakistan 13
LT - Lituania 13
AL - Albania 12
PT - Portogallo 12
IL - Israele 11
MK - Macedonia 10
NP - Nepal 10
DK - Danimarca 9
ET - Etiopia 9
HN - Honduras 9
RS - Serbia 9
TN - Tunisia 9
UY - Uruguay 9
SK - Slovacchia (Repubblica Slovacca) 8
BG - Bulgaria 7
GE - Georgia 7
HU - Ungheria 7
KR - Corea 7
LY - Libia 7
MY - Malesia 7
RO - Romania 7
AZ - Azerbaigian 6
BB - Barbados 6
BH - Bahrain 6
DO - Repubblica Dominicana 6
LB - Libano 6
PS - Palestinian Territory 6
BO - Bolivia 5
IR - Iran 5
KG - Kirghizistan 5
KW - Kuwait 5
LU - Lussemburgo 5
NO - Norvegia 5
SN - Senegal 5
SV - El Salvador 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
BY - Bielorussia 4
CI - Costa d'Avorio 4
KH - Cambogia 4
LV - Lettonia 4
AM - Armenia 3
GT - Guatemala 3
LK - Sri Lanka 3
Totale 31.992
Salva come PNG Salva come JPEG
Città #
Fairfield 1.489
Singapore 1.370
Ashburn 1.217
Woodbridge 1.174
Hong Kong 998
Houston 840
Jacksonville 833
Warsaw 767
San Jose 630
The Dalles 574
Seattle 570
Cambridge 545
Wilmington 513
Ann Arbor 491
Beijing 481
Princeton 439
New York 422
Chandler 346
Helsinki 291
Los Angeles 262
Istanbul 244
Dublin 239
Lauterbourg 234
Nanjing 227
Ho Chi Minh City 200
Columbus 168
Council Bluffs 151
Munich 149
São Paulo 144
Dallas 142
Brescia 136
Hanoi 134
Milan 122
Moscow 117
Buffalo 107
Redondo Beach 107
San Diego 103
Nanchang 102
Nürnberg 102
Des Moines 95
Changsha 86
Shanghai 85
Chicago 82
San Francisco 82
Santa Clara 81
Shenyang 69
Hebei 65
London 65
Lancaster 63
Nuremberg 52
Orem 52
Rio de Janeiro 52
Turku 52
Tokyo 47
Chennai 44
Jinan 43
Rome 42
Toronto 40
Johannesburg 39
Abuja 37
Atlanta 37
Brooklyn 36
Hangzhou 35
Tianjin 35
Belo Horizonte 34
Denver 33
Phoenix 33
Bergamo 32
Dearborn 32
Jiaxing 32
Mexico City 31
Porto Alegre 29
Guangzhou 28
Haiphong 28
Poplar 28
Zhengzhou 28
Amsterdam 27
Curitiba 27
Da Nang 27
Frankfurt am Main 27
Montreal 27
Dhaka 26
Verona 26
Brasília 25
Manchester 25
Tashkent 25
Dong Ket 24
Biên Hòa 23
Romola 23
Boardman 22
Kunming 21
Amman 19
Baghdad 19
Brussels 19
Charlotte 19
Guayaquil 19
Brno 18
Lanzhou 18
Mumbai 18
Stockholm 18
Totale 19.506
Salva come PNG Salva come JPEG
Nome #
9A.07: CARDIOVASCULAR TARGET ORGAN DAMAGE IN PREMENOPAUSAL SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IN CONTROLS. ARE THERE ANY DIFFERENCES? 343
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome 322
Role of guanylate binding protein-1 in vascular defects associated with chronic inflammatory diseases. 295
The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation 257
Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder? 237
Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis 237
Long-term outcome of children of rheumatic disease patients 234
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 221
The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus 213
Antirheumatic drugs and reproduction in women and men with chronic arthritis. 211
SINDROME DA ANTICORPI ANTIFOSFOLIPIDI E LESIONI PUNTIFORMI DELLA SOSTANZA BIANCA ALLA RISONANZA MAGNETICA. QUAL E' IL LORO SIGNIFICATO? VALUTAZIONE DI 169 PAZIENTI CON MANIFESTAZIONI NEUROLOGICHE 209
14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome 208
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 208
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends 201
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. 192
A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus 192
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 191
Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes 187
Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. 186
Typing TREX1 Gene In Patients With Systemic Lupus Erythematosus. 185
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 185
Anti-phospholipid antibodies 183
Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: performance of new commercial ELISA kits. 182
Children born to SLE and APS mothers 182
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 181
Management of thrombotic and obstetric antiphospholipid syndrome: A systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults 180
A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus 177
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 176
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome 174
Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis 173
25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies. 172
Antiphospholipid antibodies mediate autoimmunity against dying cells. 172
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 171
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 171
Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. 170
Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 169
Inflammatory molecules: A target for treatment of systemic autoimmune diseases. 167
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 167
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 166
The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes 164
Subpopulations of anti-β₂glycoprotein I antibodies with different pathogenic potential: fine specificity against the domains of β₂glycoprotein I 163
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 163
Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome 161
Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study 160
Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'. 159
Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? 155
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 155
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome 155
Long-term outcome of children born from mothers with autoimmune diseases 155
Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: Results from a multicenter study of 283 pregnancies 154
Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D 152
Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? 151
APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. 151
Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. 151
State of the art: Reproduction and pregnancy in rheumatic diseases. 151
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: 'Colchicine treatment in community healthcare setting to prevent severe COVID-19' by Della-Torre et al 151
Are the current attempts at standardization of antiphospholipid antibodies still useful? Emerging technologies signal a shift in direction. 150
Antiphospholipid antibody profile: implications for the evaluation and management of patients. 150
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 150
Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7 150
Beyond the "syndrome": antiphospholipid antibodies as risk factors. 149
Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. 149
ANTI-BETA2 GLYCOPROTEIN I-DOMAIN 1 AUTOANTIBODIES: COMPARISON BETWEEN TWO METHODS OF DETECTION 149
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 149
Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome. 148
Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome 148
PROSPECTIVELY FOLLOWED PREGNANCIES IN PATIENTS WITH SYSTEMIC VASCULITIS: STILL MANY PROBLEMS ON BOTH FOETAL AND MATERNAL SIDE 147
Management of recurrent thrombosis in antiphospholipid syndrome 147
European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO) 147
EFFICACY AND SAFETY OF CYCLOSPORINE-A DURING PREGNANCY IN AUTOIMMUNE DISEASES 146
An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases 146
Predictors of maternal and fetal complications in SLE patients: a prospective study 145
Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases 145
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. 144
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. 144
Pregnancy in patients with autoimmune disease: A reality in 2016 143
Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi–Goutières Syndrome 142
Development of automated assays for anticardiolipin antibodies determination: addressing antigen and standardization issues. 141
Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: may antinucleosome antibodies be predictive? 140
Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. 140
Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. 138
Neonatal effects of maternal antiphospholipid syndrome. 138
A PROSPECTIVE STUDY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS SUPPLEMENTED WITH TWO DIFFERENT REGIMES OF VITAMIN D: EFFICACY AND SAFETY AT SIX MONTHS OF FOLLOW-UP 138
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients 138
I polimorfismi della metilentetraidrofolatoreduttasi (MTHFR) nel trattamento con methotrexate di pazienti con artrite reumatoide. Revisione della letteratura ed esperienza personale. 136
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 135
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy 135
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 134
Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. 134
DOMAIN 1 IS THE MAIN SPECIFICITY OF ANTI-BETA2GPI ANTIBODIES IN SYSTEMIC AUTOIMMUNE DISEASES 134
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 134
A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution 134
The Efficacy and Safety of Cyclosporin A in Pregnant Patients with Systemic Autoimmune Diseases 133
Infertility in women with systemic autoimmune diseases 133
IL COMPLEMENTO NELLA GRAVIDANZA DI DONNE AFFETTE DA SINDROME DA ANTICORPI ANTIFOSFOLIPIDI PRIMARIA 132
Vitamin D and antiphospholipid syndrome. 130
Small extracellular vesicle-delivered microRNAs promote IFN-alpha secretion by plasmacytoid DCs via TLR7 130
Belimumab decreases flare rate and hinders the expected damage progression in patients with active systemic lupus erythematosus 129
The estimated frequency of Antiphospholipid antibodies in young adults with cerebrovascular events: A systematic review 129
Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic 126
Totale 16.677
Salva come PNG Salva come JPEG
Categoria #
all - tutte 159.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 159.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.649 0 280 54 102 20 102 57 132 103 206 172 421
2022/20231.285 248 16 32 58 125 377 5 107 176 4 65 72
2023/20241.814 108 64 144 158 66 345 56 78 456 33 26 280
2024/20254.520 84 71 66 530 408 411 509 247 392 351 915 536
2025/20269.760 856 1.383 744 1.497 911 608 1.351 371 549 869 364 257
2026/2027717 467 250 0 0 0 0 0 0 0 0 0 0
Totale 32.502